PAMP
JBIO

Polar Asset Management Partners’s Jade Biosciences JBIO Stock Holding History

Polar Asset Management Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-602
Closed -$481K – 1232
2021
Q2 		$481K Buy
+602
New +$481K ﹤0.01% 797

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Polar Asset Management Partners's JBIO Position: Q3 2021 in Review

Polar Asset Management Partners sold out of Jade Biosciences (JBIO) in Q3 2021, closing a stake of 602 shares — an estimated $481K sold.

Polar Asset Management Partners first reported a position in JBIO in Q2 2021 and held it in 1 quarter. The position peaked at $481K in Q2 2021. 41 funds tracked by Wall St. Rank hold JBIO as of Q3 2021.

  • Polar Asset Management Partners reported no remaining Jade Biosciences position as of Q3 2021 after selling out during the quarter.
  • Polar Asset Management Partners sold 602 Jade Biosciences shares in Q3 2021, an estimated $481K.
  • Polar Asset Management Partners first reported a position in Jade Biosciences in Q2 2021 and held it in 1 quarter.
  • Polar Asset Management Partners's Jade Biosciences position peaked at $481K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2021.

Based on Polar Asset Management Partners's 13F filing for Q3 2021, filed 15 Nov 2021.